Cortexa Therapeutics

About Us

Cortexa Therapeutics is a biotech startup pioneering a new era in the treatment of Amyotrophic Lateral Sclerosis (ALS). Founded by a Marine Corps officer diagnosed with ALS at 31, our mission is deeply personal—driven by urgency, innovation, and the belief that patients deserve more than incremental progress.

Unlike traditional approaches, Cortexa targets ALS at its root, focusing on the underlying mechanisms of neuronal degeneration through a dual-pathway approach that addresses both excitotoxicity and calcium dysregulation. This precision-driven model represents an untapped therapeutic frontier in ALS and related neurodegenerative diseases. With a streamlined development strategy and an unwavering commitment to rapid translation, Cortexa aims to bring its first treatment to human trials within a year—because ALS patients don’t have time to wait.

Our work holds promise not only for ALS, but also for conditions such as Alzheimer’s, Parkinson’s, and frontotemporal dementia, where neuroprotection and cellular resilience are critical to change outcomes.